


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:


Listing of Claims:

1. (Original) A compound having Formula I or salts, hydrates or solvates thereof and comprising at least one radiolabel:



FORMULA I

2. (Original) A compound as claimed in claim 1 wherein the said compound comprises at least 1, 2 or 3 tritium substitutions in the meta position.
3. (Original) A compound of Formula II:




FORMULA II

or salts thereof.

4. (Currently amended) ~~An assay for characterising~~ A method of characterizing the activity of a compound as an I_{Kr} channel blocker comprising the following steps:

- a) ~~incubation of~~ incubating a cell membrane containing the I_{Kr} channel in the presence of the compound of Formula II




Formula II

in the presence or absence of a test compound;

- b) ~~determination of~~ determining specifically bound ~~labelled~~ labeled compound in the presence or absence of a test compound;
- c) ~~calculation of~~ calculating the inhibition of ~~labelled~~ labeled compound binding by the test compound.

5. (Currently amended) The method of ~~An assay as claimed in~~ claim 4 comprising the steps of :
- a) preparing solutions of test compound at one or more concentrations;
 - b) mixing the compound of Formula II with the cell membrane containing the I_{Kr} channel;
 - c) incubating the solutions of test compound with the mixture of compound of Formula II and cell membrane containing the I_{Kr} channel;
 - d) isolating the membrane from the solutions and measuring the radioactivity of the membrane;
 - e) calculating the radioactivity of samples in the presence of test compound compared to a control in the absence of test compound.
6. (Currently amended) The method of ~~An assay as claimed in~~ claim 4 ~~or claim 5~~ wherein the I_{Kr} channel is human ERG.
7. (Currently amended) The method of ~~An assay as claimed in~~ claim 6 wherein the cell membrane is derived from a cell line transfected with the human ERG gene.
8. (Currently amended) The method of ~~An assay as claimed in~~ claim 7 wherein the cell line is HEK.
9. (Currently amended) A method of assaying one or more candidate compounds comprising ~~Use of a compound of Formula II in an assay for~~ characterising the I_{Kr} channel blocker activity of one or more candidate compounds using a compound of Formula II



Formula II.

10. (Currently amended) ~~A use as claimed in~~ The method of claim 9 wherein the assay is a competitive binding assay.
11. (Original) A process for preparing a compound of Formula II as defined in claim 3, said process comprising tritiating 3,7-Bis[2-(4-nitrophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane in the presence of (1,5-cyclooctadiene)bis(methyldiphenyl-phosphine)iridium(I) hexafluorophosphate.
12. (Original) A process as claimed in claim 11 wherein the 3,7-Bis[2-(4-nitrophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane and (1,5-cyclooctadiene)bis(methyldiphenyl-phosphine)iridium(I) hexafluorophosphate are dissolved in dichloromethane.
13. (Currently amended) A process as claimed in claim 11 ~~or claim 12~~ wherein tritiation is carried out using a tritiation manifold.
14. (Cancelled)